P. Novoa

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 215 citations · Full text

Pharmacy, Nephrology, Pharmacotherapy +13

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease

Zien Zhou, Meg Jardine, Qiang Li et al. · Stroke · 2021 · 118 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial

Lionel Rostaing, Suphamai Bunnapradist, Josep M. Grinyó et al. · American Journal of Kidney Diseases · 2015 · 101 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Uremic pruritus in hemodialysis patients: treatment with desloratidine versus gabapentin

Diego Márquez, C. Paulina Ramonda, Jorge E. Lauxmann et al. · Brazilian Journal of Nephrology · 2012 · 41 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Results of the Conversion to Everolimus in Renal Transplant Recipients With Posttransplantation Malignancies

Carlos Chiurchiu, Cristian Alonso Duarte Carreño, Rubén Schiavelli et al. · Transplantation Proceedings · 2010 · 38 citations

Medicine, Nephrology, Surgery +14